Calidi Biotherapeutics Inc Ordinary Shares CLDI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Calidi Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Calidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors into Localized TCE Biofactories
Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026
Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency
Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Trading Information
- Previous Close Price
- $0.62
- Day Range
- $0.59–0.65
- 52-Week Range
- $0.59–24.80
- Bid/Ask
- $0.50 / $0.72
- Shares Outstanding
- 3.45M
- Market Cap
- $1.56M
- Volume/Avg
- 39,272 / 111,359
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 29
- Website
- https://www.calidibio.com
Valuation
Metric | CLDI |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.41 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
CLDI
Financial Strength
Metric | CLDI |
|---|---|
Quick Ratio | 1.34 |
Current Ratio | 1.68 |
Interest Coverage | −111.12 |
Quick Ratio
CLDI
Profitability
Metric | CLDI |
|---|---|
Return on Assets (Normalized) | −170.26% |
Return on Equity (Normalized) | −407.06% |
Return on Invested Capital (Normalized) | −235.63% |
Return on Assets
CLDI
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|knfY^Z? | LOCK|!rVx | $136B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|Q@%<Q%f | LOCK|d^Td | $99B | |||
| Moderna Inc MRNA | LOCK|%<<?rx | LOCK|?> | $87B | |||
| argenx SE ADR ARGX | LOCK|M$GFbWG | LOCK|Yn% | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|zx^PbHm | LOCK|hS | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|FB?MTHK | LOCK|!z#>> | $31B | |||
| Incyte Corp INCY | LOCK|n!CN&D | LOCK|$dN | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|&wp%KP | LOCK|^C?K | $21B | |||
| BioNTech SE ADR BNTX | LOCK|V@TT^g! | LOCK|Y! | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|@pWYg^ | LOCK|HHw | $15B |